[Retroperitoneal fibrosis due to ergotamine. Apropos a case]

Area of Science:

• Nephrology
• Radiology
• Pharmacology

Background:

• Retroperitoneal fibrosis (RPF) is a rare condition characterized by inflammatory tissue in the retroperitoneum.
• Ergotamine, a medication used for migraines, has been implicated as a potential cause of drug-induced RPF.
• Early diagnosis and identification of the causative agent are critical for effective management.

Observation:

• A case study of a young patient presenting with RPF secondary to chronic ergotamine use is detailed.
• The patient's symptoms and imaging findings were consistent with ergotamine-induced fibrotic changes.
• Discontinuation of ergotamine led to the remission of the retroperitoneal fibrous plaque.

Findings:

• Contrast-enhanced computed tomography (CT) is a highly effective imaging modality for diagnosing RPF.
• CT allows for precise delineation of the extent and characteristics of the retroperitoneal lesion.
• The study underscores the diagnostic value of contrast-enhanced CT in RPF cases.

Implications:

• This review highlights the importance of considering ergotamine as a potential cause of RPF in patients with relevant exposure.
• Contrast-enhanced CT should be a primary diagnostic tool for RPF, aiding in treatment decisions and follow-up.
• Understanding the link between ergotamine and RPF can improve patient outcomes through timely intervention and medication review.